Summary & Overview
CPT 0114U: EsoGuard Methylation Test for Barrett’s Esophagus
CPT code 0114U designates the EsoGuard™ Proprietary Laboratory Analyses (PLA) test from Lucid Diagnostics, a molecular diagnostic that assesses cytosine methylation of esophageal cells collected with a swallowed balloon device to detect methylation of VIM and CCNA1—markers predictive of Barrett’s esophagus. As a PLA code, 0114U is specific to a single manufacturer's test and signals distinct coding, billing, and coverage considerations for molecular diagnostics across payers. Nationally, adoption of PLA-coded tests affects laboratory billing workflows and payer coverage policies for minimally invasive esophageal cancer screening tools.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find consolidated information on payer coverage patterns, common billing modifiers used with complex molecular lab services, and clinical context about the EsoGuard™ test’s sampling method and reported results. The publication also provides benchmarks and policy updates relevant to PLA-coded diagnostics, operational guidance on site-of-service considerations, and implications for coding and reimbursement processes. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0114U is a Proprietary Laboratory Analyses (PLA) code for the EsoGuard™ test developed by Lucid Diagnostics. The test uses cytosine methylation analysis of esophageal cells obtained from a swallowed balloon device and applies an algorithm to report the presence or absence of VIM and CCNA1 methylation, a predictor of Barrett’s esophagus.
Service type: Laboratory molecular diagnostic test using methylation analysis of esophageal samples obtained via a swallowed balloon device.
Typical site of service: Outpatient clinic, ambulatory procedure center, or laboratory setting where the swallowed balloon collection device is administered and specimens are processed by the performing laboratory.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with chronic gastroesophageal reflux disease (GERD) and confirmed or suspected columnar-appearing esophagus on endoscopy is evaluated for noninvasive screening for Barrett’s esophagus. A primary care physician or gastroenterologist orders the EsoGuard™ test (reportable with 0114U). The patient swallows a single-use balloon cytology device per manufacturer instructions in an outpatient clinic or ambulatory infusion/diagnostic lab; cells are collected during retrieval of the device and sent to the proprietary laboratory. The laboratory performs cytosine methylation analysis of esophageal cells and runs an algorithm that reports presence or absence of VIM and CCNA1 methylation as a predictor of Barrett’s esophagus. Results are returned to the ordering clinician who integrates the molecular test result with clinical findings (symptoms, endoscopy, biopsy results if available) to guide surveillance or referral to gastroenterology. Typical site of service: outpatient clinic, ambulatory surgery center, or reference laboratory for the analytic component. Typical patient scenario: symptomatic GERD with risk factors (long-standing reflux, age >50, male sex, hiatal hernia) undergoing a minimally invasive screening test when endoscopy is deferred or as an adjunct to endoscopic assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting the professional interpretation component separately from the laboratory analytic component (if applicable and payer allows). |